

# Kyle Wierzbicki

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2058586/publications.pdf>

Version: 2024-02-01

9  
papers

222  
citations

1478505

6  
h-index

1588992

8  
g-index

12  
all docs

12  
docs citations

12  
times ranked

330  
citing authors

#	ARTICLE	IF	CITATIONS
1	CSF H3F3A K27M circulating tumor DNA copy number quantifies tumor growth and in vitro treatment response. <i>Acta Neuropathologica Communications</i> , 2018, 6, 80.	5.2	50
2	Everolimus improves the efficacy of dasatinib in PDGFR $\pm$ -driven glioma. <i>Journal of Clinical Investigation</i> , 2020, 130, 5313-5325.	8.2	41
3	Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma. <i>Neuro-Oncology</i> , 2022, 24, 1366-1374.	1.2	36
4	Targeting and Therapeutic Monitoring of H3K27M-Mutant Glioma. <i>Current Oncology Reports</i> , 2020, 22, 19.	4.0	35
5	Standardization of the liquid biopsy for pediatric diffuse midline glioma using ddPCR. <i>Scientific Reports</i> , 2021, 11, 5098.	3.3	31
6	Electronic DNA Analysis of CSF Cell-free Tumor DNA to Quantify Multi-gene Molecular Response in Pediatric High-grade Glioma. <i>Clinical Cancer Research</i> , 2020, 26, 6266-6276.	7.0	26
7	PDCT-12. CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA. <i>Neuro-Oncology</i> , 2019, 21, vi186-vi186.	1.2	2
8	PDTM-29. CSF H3F3A K27M CIRCULATING TUMOR DNA COPY NUMBER QUANTIFIES TUMOR GROWTH AND TREATMENT RESPONSE. <i>Neuro-Oncology</i> , 2018, 20, vi209-vi210.	1.2	0
9	EPCT-03. SERIAL PLASMA AND CSF CELL-FREE TUMOR DNA (CF-TDNA) TRACKING IN DIFFUSE MIDLINE GLIOMA PATIENTS UNDERGOING TREATMENT WITH ONC201. <i>Neuro-Oncology</i> , 2021, 23, i46-i47.	1.2	0